- Home
- FMS vs IART Comparison
FMS vs IART Comparison
Compare FMS & IART Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMS
- IART
- Stock Information
- Founded
- FMS 1996
- IART 1989
- Country
- FMS Germany
- IART United States
- Employees
- FMS 111513
- IART N/A
- Industry
- FMS Misc Health and Biotechnology Services
- IART Medical/Dental Instruments
- Sector
- FMS Health Care
- IART Health Care
- Exchange
- FMS Nasdaq
- IART Nasdaq
- Market Cap
- FMS 13.8B
- IART N/A
- IPO Year
- FMS 1996
- IART 1995
- Fundamental
- Price
- FMS $24.46
- IART $16.81
- Analyst Decision
- FMS Hold
- IART Hold
- Analyst Count
- FMS 1
- IART 8
- Target Price
- FMS $25.00
- IART $24.33
- AVG Volume (30 Days)
- FMS 428.6K
- IART 671.0K
- Earning Date
- FMS 05-06-2025
- IART 05-05-2025
- Dividend Yield
- FMS 2.59%
- IART N/A
- EPS Growth
- FMS 7.65
- IART N/A
- EPS
- FMS 1.89
- IART N/A
- Revenue
- FMS $20,018,541,263.00
- IART $1,610,527,000.00
- Revenue This Year
- FMS $5.05
- IART $6.36
- Revenue Next Year
- FMS $3.90
- IART $4.32
- P/E Ratio
- FMS $25.68
- IART N/A
- Revenue Growth
- FMS N/A
- IART 4.47
- 52 Week Low
- FMS $17.93
- IART $15.95
- 52 Week High
- FMS $25.96
- IART $32.66
- Technical
- Relative Strength Index (RSI)
- FMS 52.98
- IART 37.10
- Support Level
- FMS $23.52
- IART $15.95
- Resistance Level
- FMS $24.32
- IART $17.26
- Average True Range (ATR)
- FMS 0.60
- IART 1.31
- MACD
- FMS -0.00
- IART 0.03
- Stochastic Oscillator
- FMS 76.51
- IART 38.69
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three quarters of sales while the balance is generated from medical technology products that enable dialysis treatments.